TICKERNOMICS Sign up
Last Update: 2023-10-04 11:35:59
Enochian Biosciences Inc ( ENOB ) https://www.enochianbio.com
1.56USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
14.73%
-19.17%
ENOB
SPY
36.71%
-56.06%
ENOB
SPY
70.96%
-73.10%
ENOB
SPY
262.36%
ENOB
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
81.94
73.81
0.92
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.00
1864.99
1.13
-30.23
0.00
-0.67
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-256462.30
87.30
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.1655
-1253975.86
-12.74
1.05
Other Earnings and Cash Flow Stats:
Enochian Biosciences Inc ( ENOB ) Net Income TTM ($MM) is -387259.55
Enochian Biosciences Inc ( ENOB ) Operating Income TTM ($MM) is -20.24
Enochian Biosciences Inc ( ENOB ) Owners' Earnings Annual ($MM) is -25.10
Enochian Biosciences Inc ( ENOB ) Current Price to Owners' Earnings ratio is -0.84
Enochian Biosciences Inc ( ENOB ) EBITDA TTM ($MM) is -20.16
Enochian Biosciences Inc ( ENOB ) EBITDA Margin is 0.00%
Capital Allocation:
Enochian Biosciences Inc ( ENOB ) has paid 0.00 dividends per share and bought back 2.979058 million shares in the past 12 months
Enochian Biosciences Inc ( ENOB ) has reduced its debt by 5.949752 million USD in the last 12 months
Capital Structure:
Enochian Biosciences Inc ( ENOB ) Interest-bearing Debt ($MM) as of last quarter is 1
Enochian Biosciences Inc ( ENOB ) Annual Working Capital Investments ($MM) are 5
Enochian Biosciences Inc ( ENOB ) Book Value ($MM) as of last quarter is 72
Enochian Biosciences Inc ( ENOB ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
Enochian Biosciences Inc ( ENOB ) has 9 million in cash on hand as of last quarter
Enochian Biosciences Inc ( ENOB ) has 6 million of liabilities due within 12 months, and long term debt 10 as of last quarter
Enochian Biosciences Inc ( ENOB ) has 52 common shares outstanding as of last quarter
Enochian Biosciences Inc ( ENOB ) has 0 million USD of preferred stock value
Academic Scores:
Enochian Biosciences Inc ( ENOB ) Altman Z-Score is -3.55 as of last quarter
Enochian Biosciences Inc ( ENOB ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Enochian Biosciences Inc ( ENOB ) largest shareholder is New York State Common Retirement Fund owning 31000 shares at 0.05 ($MM) value
Serhat Gumrukcu(an insider) Sold 253493 shares of Enochian Biosciences Inc ( ENOB ) for the amount of $2027944.00 on 2022-05-18
58.06% of Enochian Biosciences Inc ( ENOB ) is held by insiders, and 6.55% is held by institutions
Enochian Biosciences Inc ( ENOB ) went public on 2015-02-02
Other Enochian Biosciences Inc ( ENOB ) financial metrics:
FCF:-12.01
Unlevered Free Cash Flow:-27.63
EPS:-29481.66
Operating Margin:-256462.30
Gross Profit Margin:87.30
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-2132522.56
Beta:1.05
Buffet's Owners Earnings:-25.10
Price to Owner's Earnings:-0.84
About Enochian Biosciences Inc ( ENOB ) :
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.